On The Radar – 22nd Edition
By
Major pharmaceutical companies are narrowing their R&D focus, placing larger investments on specialized therapies like antibody-drug conjugates and nucleic acid-based treatments. While this strategy may accelerate innovation, it also raises the stakes if high-profile clinical trials fail.
➡ Why it matters: The industry is shifting toward “high-risk, high-reward” pipelines as patent cliffs and pricing pressure intensify.
TrumpRx.gov has expanded its marketplace to include more than 600 generic medications through partnerships with providers like Amazon Pharmacy and Cost Plus Drugs. The platform allows consumers to compare transparent cash prices and home-delivery options.
➡ Why it matters: Direct-to-consumer pricing tools continue gaining traction as patients search for lower-cost alternatives outside traditional benefit models.
Artificial intelligence is beginning to automate core PBM functions like prior authorizations, formulary optimization, and claims management. Legacy PBMs face growing pressure as AI-powered platforms increase transparency and reduce administrative friction.
➡ Why it matters: Technology may fundamentally disrupt traditional PBM revenue models built around opaque pricing and manual workflows.
Drug manufacturers are increasingly adopting integrated direct-to-patient (DTP) strategies that simplify prior authorizations, automate financial assistance, and streamline prescription fulfillment.
➡Why it matters: DTP models are reducing dependence on traditional intermediaries while improving visibility into patient access and adherence.
New federal rules tied to the Consolidated Appropriations Act and Department of Labor proposals are increasing compliance expectations for employer-sponsored health plans and PBMs.
➡Why it matters: Employers now face greater fiduciary responsibility to actively monitor pharmacy spending, rebates, and PBM compensation structures.
AHIP is calling attention to “patent thickets,” product hopping, and other tactics used by manufacturers to delay generic competition and maintain high drug prices.
➡Why it matters: Patent reform continues emerging as a major lever in the fight against rising prescription drug costs.
The Trump administration continues expanding its affordability initiatives through Most Favored Nation pricing efforts, direct-to-consumer discount platforms, and voluntary manufacturer agreements.
➡ Why it matters: Federal policymakers are increasingly pushing transparency and direct pricing strategies into the center of healthcare reform discussions.
Biotech and pharmaceutical investors are closely watching the industry’s looming patent cliff, which could eliminate billions in annual branded drug revenue over the next several years.
➡ Why it matters: Patent expirations may fuel increased mergers, acquisitions, and competition across the biotech landscape.
Employers report that demand for GLP-1 medications is creating substantial financial strain on health plans, forcing many organizations to tighten utilization management and reevaluate coverage strategies.
➡ Why it matters: GLP-1s remain one of the fastest-growing and most disruptive cost drivers in employer healthcare today.
A new survey found overwhelming employer support for rebate-free PBM structures that prioritize upfront discounts and transparent fee-based pricing over traditional rebate arrangements.
➡ Why it matters: Plan sponsors are increasingly rejecting opaque rebate-driven models in favor of simpler, more predictable pharmacy pricing.
States continue advancing aggressive PBM reform legislation targeting spread pricing, patient steering, and rebate transparency, while federal enforcement actions gain momentum.
➡ Why it matters: The pharmacy benefit landscape is rapidly shifting toward tighter regulation, greater transparency, and increased fiduciary accountability.
Final Thoughts
The healthcare industry continues moving away from opaque pricing structures and passive benefit management models. Between AI disruption, expanding transparency requirements, growing employer scrutiny, and mounting pressure on PBMs and manufacturers, organizations are being forced to rethink how pharmacy benefits are purchased, managed, and delivered in 2026.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.